Overall The University of Arizona Cancer Center (UACC) in Tucson, Arizona has been an NCI-designated Cancer Center since 1978 and a Comprehensive Cancer Center since 1990. It was founded as a matrix center within the University of Arizona (UA), and its members represent 43 Colleges and 11 Departments. In 2014, the UACC was elevated to a status equivalent to that of a College, reporting directly to the Senior Vice President of Health Sciences. At this time, Andrew S. Kraft, MD, was appointed Director of the UACC. With authority for all cancer-related activities at the UA, he is spearheading the utilization of the significant Institutional support to enhance the Program. This includes the recently completed $100M 220,000 square foot outpatient clinic in Phoenix, which will greatly enhance translational research, an expansion of basic research space with occupancy of 20,000 square feet within two years, and an Institutional Commitment of $232M dollars over the next five years. The functionality of the Center has been enhanced by optimization of the Administration and Senior Leadership infrastructure. The UACC Strategic Plan for 2015?2020 calls for the continuation of the highly innovative and impactful team science based on four robust cornerstone Programs: Cancer Biology, Cancer Imaging, Therapeutic Development, and Cancer Prevention and Control. Strategic recruitment and pilot funding is focused on team building, including development of inter-programmatic collaborations and movement of research into the clinic. The UACC will continue to invest in its eight integrated Shared Resources that enhance the capabilities of UACC investigators in basic, prevention, translational, and clinical research, and another in development. The Clinical Trials Office has been strengthened, and investments supporting precision medicine initiatives are ongoing. The UACC is the only major academic Cancer Center in a 400 square mile area of driving distance and is committed to serving the residents in this region and its direct catchment area of southern Arizona. Thus, it has a focus on skin cancer and arsenic exposure as well as the needs of Hispanics, Native Americans, the elderly, and the economically disadvantaged. It has established a robust infrastructure of international, national, and regional collaborations and outreach programs together with research spanning epidemiology, genetics, epigenetics, cell biology, and signaling mechanisms, as well as targeted interventions and understudied survivorship issues. To capture the emerging synergies, the positions of Associate Director of Cancer Disparities and Associate Director of Precision Medicine and Bioinformatics have been created and filled by nationally recognized experts. The UACC emphasis on inclusive training of the next generation of cancer researchers has had demonstrable success in graduation of Native American and Latinos. The research generated by UACC members is characterized by its impact, its relevance to the catchment area, and its innovation. The Strategic Plan builds on the work that has resulted in 1,756 cancer- related publications in the reporting period and its current portfolio of $44M in peer-reviewed support.

Public Health Relevance

The University of Arizona Cancer Center (UACC) in Tucson, Arizona has been an NCI-designated Cancer Center since 1978 and a Comprehensive Cancer Center since 1990. Its four major research areas fall into the following organized scientific programs: Cancer Biology, Cancer Imaging, Therapeutic Development, and Cancer Prevention and Control. UACC has a research focus on skin cancer and arsenic exposure, as well as the cancer health needs of Hispanics and Native Americans, the elderly, and the economically disadvantaged.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA023074-40S5
Application #
10257253
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-07-01
Project End
2021-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
40
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Arizona
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Lent, Adrienne B; O'Connor, Patrick A; Reikowsky, Ryan C et al. (2018) Quit outcomes among clients ineligible for cessation medication through the state quitline: a retrospective, observational study. BMC Public Health 18:1001
Bea, J W; Hsu, C-H; Blew, R M et al. (2018) Use of iDXA spine scans to evaluate total and visceral abdominal fat. Am J Hum Biol 30:
Bulkley, Joanna E; McMullen, Carmit K; Grant, Marcia et al. (2018) Ongoing ostomy self-care challenges of long-term rectal cancer survivors. Support Care Cancer 26:3933-3939
Zaim, Samir Rachid; Li, Qike; Schissler, A Grant et al. (2018) Emergence of pathway-level composite biomarkers from converging gene set signals of heterogeneous transcriptomic responses. Pac Symp Biocomput 23:484-495
Kobes, Joseph E; Georgiev, George I; Louis, Anthony V et al. (2018) A Comparison of Iron Oxide Particles and Silica Particles for Tracking Organ Recellularization. Mol Imaging 17:1536012118787322
Kelly, K R; Espitia, C M; Zhao, W et al. (2018) Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia 32:230-233
Downs, Charles A; Johnson, Nicholle M; Tsaprailis, George et al. (2018) RAGE-induced changes in the proteome of alveolar epithelial cells. J Proteomics 177:11-20
Sun, Virginia; Wendel, Christopher S; Demark-Wahnefried, Wendy et al. (2018) Diet and Behavior Modifications by Long-term Rectal Cancer Survivors to Manage Bowel Dysfunction-Associated Symptoms. Nutr Cancer :1-11
Mushtaq, Adeela; Kapoor, Vikas; Latif, Azka et al. (2018) Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol 125:1-11
Rak, Michael A; Buehler, Jason; Zeltzer, Sebastian et al. (2018) Human Cytomegalovirus UL135 Interacts with Host Adaptor Proteins To Regulate Epidermal Growth Factor Receptor and Reactivation from Latency. J Virol 92:

Showing the most recent 10 out of 1336 publications